- Home
- ATIF vs COEP Comparison
ATIF vs COEP Comparison
Compare ATIF & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- COEP
- Stock Information
- Founded
- ATIF 2015
- COEP 2017
- Country
- ATIF United States
- COEP United States
- Employees
- ATIF N/A
- COEP N/A
- Industry
- ATIF Professional Services
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATIF Consumer Discretionary
- COEP Health Care
- Exchange
- ATIF Nasdaq
- COEP Nasdaq
- Market Cap
- ATIF 8.9M
- COEP 7.3M
- IPO Year
- ATIF 2019
- COEP N/A
- Fundamental
- Price
- ATIF $0.64
- COEP $0.19
- Analyst Decision
- ATIF
- COEP
- Analyst Count
- ATIF 0
- COEP 0
- Target Price
- ATIF N/A
- COEP N/A
- AVG Volume (30 Days)
- ATIF 364.5K
- COEP 685.7K
- Earning Date
- ATIF 12-31-2024
- COEP 11-13-2024
- Dividend Yield
- ATIF N/A
- COEP N/A
- EPS Growth
- ATIF N/A
- COEP N/A
- EPS
- ATIF N/A
- COEP N/A
- Revenue
- ATIF $620,000.00
- COEP N/A
- Revenue This Year
- ATIF N/A
- COEP N/A
- Revenue Next Year
- ATIF N/A
- COEP N/A
- P/E Ratio
- ATIF N/A
- COEP N/A
- Revenue Growth
- ATIF N/A
- COEP N/A
- 52 Week Low
- ATIF $0.58
- COEP $0.15
- 52 Week High
- ATIF $1.50
- COEP $0.97
- Technical
- Relative Strength Index (RSI)
- ATIF 43.99
- COEP 60.23
- Support Level
- ATIF $0.70
- COEP $0.17
- Resistance Level
- ATIF $1.25
- COEP $0.20
- Average True Range (ATR)
- ATIF 0.10
- COEP 0.02
- MACD
- ATIF 0.01
- COEP 0.00
- Stochastic Oscillator
- ATIF 6.39
- COEP 69.05
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.